When Can the Pto Extend a Patent S Term Due to Delay From an Appeal
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Before Taranto, Bryson, and Hughes. Appeal from the United State District Court for the Eastern District of Virginia
Summary: An examiner’s self-reversal may not qualify as “reversing an adverse determination.”
In 2006, Chudik applied for a patent for a shoulder surgery guide. Following the Examiner’s second rejection of the pending claims in 2010, Chudik requested continued examination. In 2014, following the Examiner’s final rejection of the pending claims, Chudik appealed to the Board. In response, the Examiner reopened prosecution and rejected the claims on new grounds. This process was repeated in 2015 and 2016. Finally, in 2017, while Chudik’s fourth appeal was pending, the Examiner withdrew some objections and, following some claim amendments, allowed some of Chudik’s patent claims. Chudik’s patent issued on May 15, 2018, eleven and a half years after filing. The PTO awarded Chudik a patent term adjustment of 2,066 days, but rejected Chudik’s argument that he was entitled to an additional 655 days for the time his four notices of appeal were pending. 35 U.S.C. § 154(b)(1)(C) governs delay due to appellate review by the Board or a federal court (C-delay). C-delay requires that “the patent [be] issued under a decision in the review reversing an adverse determination of patentability.” The PTO concluded that the C-delay provision does not apply here because (1) the Board’s jurisdiction over the appeals never attached and (2) there was no Board reversal. Chudik then filed a complaint against the PTO in district court, alleging that he was entitled to the additional 655 days of C-delay. The district court rejected Chudik’s challenge, and Chudik appealed.
On appeal, Chudik argued that the Examiner reversed an adverse determination of patentability by reopening examination and allowing patent claims after Chudik appealed to the Board. The Federal Circuit disagreed, reasoning that “appellate review,” ordinarily means that a separate party must determine the merits of the review. Therefore, the Examiner’s self-reversal did not fall qualify as “reversing an adverse determination” under § 154(b)(1)(C)(iii). The Federal Circuit affirmed without resolving the PTO’s other grounds for its denial—when jurisdiction over an appeal to the Board attaches.
Editor: Paul Stewart
Written by: Adam Aquino & Karen Cassidy
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…